These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 38362536)
1. Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature. Khorasanchi A; Korman AM; Manne A; Meara A Front Med (Lausanne); 2024; 11():1334718. PubMed ID: 38362536 [TBL] [Abstract][Full Text] [Related]
2. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. Marano AL; Clarke JM; Morse MA; Shah A; Barrow W; Selim MA; Hall RP; Cardones AR Br J Dermatol; 2019 Sep; 181(3):580-583. PubMed ID: 30244487 [TBL] [Abstract][Full Text] [Related]
3. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. Zitouni NB; Arnault JP; Dadban A; Attencourt C; Lok CC; Chaby G Melanoma Res; 2019 Apr; 29(2):212-215. PubMed ID: 30489484 [TBL] [Abstract][Full Text] [Related]
5. Subacute cutaneous lupus erythematosus with a possible paraneoplastic association with melanoma. Hirner J BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31780613 [TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors and Lupus Erythematosus. Vitzthum von Eckstaedt H; Singh A; Reid P; Trotter K Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399467 [TBL] [Abstract][Full Text] [Related]
7. Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by Durvalumab: A Case Report and Literature Review. Pratumchart N; Chanprapaph K; Topibulpong N; Tankunakorn J Clin Cosmet Investig Dermatol; 2022; 15():51-62. PubMed ID: 35046689 [TBL] [Abstract][Full Text] [Related]
8. De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation. Bui AN; Hirner J; Singer SB; Eberly-Puleo A; Larocca C; Lian CG; LeBoeuf NR Clin Exp Dermatol; 2021 Mar; 46(2):328-337. PubMed ID: 32939795 [TBL] [Abstract][Full Text] [Related]
9. Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab. Kosche C; Owen JL; Choi JN Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735010 [TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors-related subacute cutaneous lupus erythematosus: Clinical characteristics, management, and outcome. Deng Z; Guo A; Wu C; Wang C J Cosmet Dermatol; 2022 Dec; 21(12):7202-7208. PubMed ID: 36214602 [TBL] [Abstract][Full Text] [Related]
11. Subacute cutaneous lupus erythematosus with a psoriasiform presentation: A diagnostic clinical conundrum. Razi S; Truong TM; Sekhon P; Ouellette S; Rao BK Clin Case Rep; 2023 Sep; 11(9):e7893. PubMed ID: 37736481 [TBL] [Abstract][Full Text] [Related]
12. Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report. Xu K; Zhang M; Yang S; Yu G; Zheng P; Qin X; Feng J BMC Neurol; 2023 Apr; 23(1):168. PubMed ID: 37101279 [TBL] [Abstract][Full Text] [Related]
13. Rowell's Syndrome Triggered by Omeprazole. Pozharashka J; Dourmishev L; Balabanova M; Vassileva S; Miteva L Acta Dermatovenerol Croat; 2019 Jun; 27(2):124-126. PubMed ID: 31351509 [TBL] [Abstract][Full Text] [Related]
14. Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in Ferro A; Filoni A; Pavan A; Pasello G; Guarneri V; Conte P; Alaibac M; Bonanno L Front Med (Lausanne); 2021; 8():570921. PubMed ID: 34179028 [TBL] [Abstract][Full Text] [Related]
15. Proton Pump Inhibitor Induced Subacute Cutaneous Lupus Erythematosus: A Case Series of 7 Patients and Brief Review of Literature. Kaur S; Singla P; Kaur S; Kansal A; Bansal A; Singh A Indian Dermatol Online J; 2022; 13(1):64-72. PubMed ID: 35198470 [TBL] [Abstract][Full Text] [Related]